Terapia PEG-Interferone alfa 2B+Ribavirina versus terapia PEG-Interferone alfa 2B + Ribavirina+ Terapia ormonale sostitutiva (TOS) nella prevenzione della progressione della fibrosi epatica nell’epatite cronica HCV positiva in eta' post-menopausale - ND

Start Date04 Mar 2008

Sponsor / Collaborator-

100 Clinical Results associated with Peginterferon alfa-2b biosimilar(Nanogen Biopharmaceutical Co)

100 Translational Medicine associated with Peginterferon alfa-2b biosimilar(Nanogen Biopharmaceutical Co)

100 Patents (Medical) associated with Peginterferon alfa-2b biosimilar(Nanogen Biopharmaceutical Co)

Literatures (Medical) associated with Peginterferon alfa-2b biosimilar(Nanogen Biopharmaceutical Co)

14 Nov 2021·World Journal of GastroenterologyQ3 · MEDICINE

Hepatitis B virus/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic

Q3 · MEDICINE

Review

Author: Pisaturo, Mariantonietta ; Sagnelli, Evangelista ; Curatolo, Caterina ; Codella, Alessio Vinicio ; Sagnelli, Caterina ; Coppola, Nicola

Hepatitis D virus (HDV) is a defective liver-tropic virus that needs the helper function of hepatitis B virus (HBV) to infect humans and replicate. HDV is transmitted sexually or by a parenteral route, in co-infection with HBV or by super-infection in HBV chronic carriers. HDV infection causes acute hepatitis that may progress to a fulminant form (7%-14% by super-infection and 2%-3% by HBV/HDV co-infection) or to chronic hepatitis (90% by HDV super-infection and 2%-5% by HBV/HDV co-infection), frequently and rapidly progressing to cirrhosis or hepatocellular carcinoma (HCC). Peg-interferon alfa the only recommended therapy, clears HDV in only 10%-20% of cases and, consequently, new treatment strategies are being explored. HDV endemicity progressively decreased over the 50 years from the identification of the virus, due to improved population lifestyles and economic levels, to the use of HBV nuclei(t)side analogues to suppress HBV replication and to the application of universal HBV vaccination programs. Further changes are expected during the severe acute respiratory syndrome coronavirus-2 pandemic, unfortunately towards increased endemicity due to the focus of healthcare towards coronavirus disease 2019 and the consequently lower possibility of screening and access to treatments, lower care for patients with severe liver diseases and a reduced impulse to the HBV vaccination policy.

01 Dec 2020·Minerva MedicaQ4 · MEDICINE

Recent news in the treatment of hepatitis B virus-related cryogobulinemic vasculitis

Q4 · MEDICINE

Review

Author: Dal Maso, Luigino ; Andreone, Pietro ; Tonizzo, Maurizio ; Visentini, Marcella ; Ermacora, Anna ; Mazzaro, Cesare ; Gattei, Valter

Hepatitis B virus (HBV) is a hepatotropic virus that causes hepatitis, cirrhosis and hepatocellular carcinoma. Twenty percent of HBV patients may develop extra-hepatic manifestations, such as polyarthritis nodosa, glomerulonephritis, dermatitis, poly-arthralgia and arthritis, and aplastic anemia. The association of HBV and cryoglobulinemic vasculitis (CV) has been highlighted by several epidemiological investigations. CV can develop in 0.5-4% of HBV infected patients. It has been demonstrated that suppression of HBV replication by nucleot(s)ide analogues (NAs) effectively induces clinical response in most patients with mild to moderate CV, but low responses are seen in severe CV. Based on this evidence, NAs therapy represents the first line therapeutic option in subjects with mild or moderate HBV related CV. Peg-interferon-Alfa can be an alternative treatment for HBV related CV, but the few studies published so far have shown no encouraging results. In patients with severe vasculitis and/or skin ulcers, peripheral neuropathy and glomerulonephritis treatment with rituximab (RTX) and NAs should be considered as a first line treatment. The long-term administration of low-medium glucocorticoid doses has been widely used in few studies to control clinical symptoms, but it should be used as a second option, when RTX is ineffective or not tolerated and in association with NAs. This review focuses on novel treatments for HBV related CV.

01 May 2019·Journal of GastroenterologyQ1 · MEDICINE

Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice

Q1 · MEDICINE

Article

Author: Takehara, Tetsuo ; Murayama, Asako ; Tatsumi, Tomohide ; Kato, Takanobu ; Doi, Akira ; Asahina, Yasuhiro ; Nitta, Sayuri ; Hikita, Hayato ; Suemizu, Hiroshi ; Saito, Yoshinobu ; Kodama, Takahiro ; Kai, Yugo ; Yamada, Ryoko ; Tahata, Yuki ; Sakamori, Ryotaro ; Nakabori, Tasuku

BACKGROUNDThe emergence of a deletion mutant at hepatitis C virus (HCV) NS5A-P32 (P32del) has recently been reported in a subset of chronic hepatitis C patients who experience virologic failure after direct-acting antiviral drug (DAA) treatment. This mutation confers extremely high resistance to NS5A inhibitors. No effective treatment has been established for cases with this mutation.METHODSWe used a JFH1-based recombinant virus with NS5A from a genotype 1b strain to introduce a P32del mutation. We inoculated human hepatocyte chimeric mice with sera from a patient with ledipasvir/sofosbuvir therapy failure carrying a genotype 1b HCV with NS5A L31M and P32del or from a DAA-naïve patient carrying wild-type virus.RESULTSJFH1-based chimeric viruses with P32del showed sufficient levels of replication for in vitro assay despite the suppression of viral growth and infectious virus production. Variants with P32del exhibited severe resistance to all tested NS5A inhibitors, including daclatasvir, ledipasvir, elbasvir and velpatasvir, but were as susceptible to NS3/4A inhibitors, NS5B inhibitors, interferon alfa-2b, and ribavirin as wild-type viruses in the in vitro assay. The P32del mutant virus caused persistent infection in all inoculated chimeric mice with high viral titer and frequency. The virus was resistant to the ledipasvir/GS-558093 (a nucleotide analog inhibitor of NS5B polymerase) regimen but susceptible to either simeprevir plus GS-558093 or peg-interferon alfa-2b, compared to the wild-type virus.CONCLUSIONTherapies combining at least two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents may be effective for HCV-infected patients with NS5A-P32del.

100 Deals associated with Peginterferon alfa-2b biosimilar(Nanogen Biopharmaceutical Co)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L03AB10	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hepatitis B	VN	Nanogen Pharmaceutical Biotechnology JSC	01 Jan 2016
Hepatitis C	VN	Nanogen Pharmaceutical Biotechnology JSC	01 Jan 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis